Analyst Price Targets — SMMT
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 24, 2026 11:57 am | — | H.C. Wainwright | $30.00 | $16.09 | TheFly | Summit Therapeutics price target lowered to $30 from $40 at H.C. Wainwright |
| January 14, 2026 11:54 am | — | Piper Sandler | $40.00 | $16.89 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Summit Therapeutics plc (SMMT) |
| December 17, 2025 7:58 am | Etzer Darout | Summit Redstone Partners | $18.00 | $17.23 | StreetInsider | Barclays Upgrades Summit Therapeutics plc (SMMT) to Equalweight |
| October 21, 2025 10:42 am | — | H.C. Wainwright | $40.00 | $20.04 | StreetInsider | Summit Therapeutics plc (SMMT) PT Lowered to $40 at H.C. Wainwright |
| October 21, 2025 9:35 am | — | Barclays | $16.00 | $20.04 | TheFly | Summit Therapeutics price target raised to $16 from $13 at Barclays |
| September 16, 2025 9:04 pm | — | Summit Redstone Partners | $13.00 | $18.12 | TheFly | Summit Therapeutics initiated with an Underweight at Barclays |
| August 19, 2025 10:31 am | Kelsey Goodwin | Summit Redstone Partners | $21.00 | $25.71 | TheFly | Piper starts Summit Therapeutics with Neutral on high expectations |
| April 28, 2025 10:11 am | — | H.C. Wainwright | $44.00 | $24.11 | TheFly | Summit Therapeutics selloff Friday on data overdone, says H.C. Wainwright |
| April 25, 2025 5:55 pm | — | Wells Fargo | $30.00 | $23.47 | TheFly | Wells says Summit, Akeso data 'not the bull case,' but not 'bear case either' |
| April 25, 2025 1:56 pm | Kelly Shi | Jefferies | $44.00 | $25.61 | TheFly | Jefferies uncovers China approval for Summit Therapeutics, ups target |
Latest News for SMMT
Summit Therapeutics Inc. (SMMT) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Wellgistics Health (NASDAQ: WGRX - Get Free Report) and Summit Therapeutics (NASDAQ: SMMT - Get Free Report) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk. Profitability This table compares Wellgistics Health and Summit
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it will participate in three upcoming investor conferences during March of this year. Members of the Summit leadership team will participate in individual investor meetings along with some fireside chats at the following conferences: TD Cowen's 46th Annual Health Care Conference in Boston…
Summit Therapeutics posts a wider Q4 loss as R&D spending surges. Its ivonescimab pipeline advances with a BLA filing and multiple late-stage cancer trials underway.
Summit Therapeutics Inc. (SMMT) Q4 2025 Earnings Call Transcript
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for SMMT.
U.S. House Trading
No House trades found for SMMT.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.